ArticleNature cancer2024
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.
Abstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review).International journal of molecular medicine · 2026Review
- Cell plasticity in cancer and therapy resistance.Experimental & molecular medicine · 2026Review
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Article
- HO-1 Nuclear Interactome Implications in Neuroendocrine Transdifferentiation in Prostate Cancer.International journal of molecular sciences · 2026Article
- SARIFA and Lipid Metabolic Reprogramming in Prostate Cancer: Fundamental Mechanisms, Tumor Microenvironment, and Novel Biomarker Prospects.Life (Basel, Switzerland) · 2026Review
- B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms.Cancers · 2026Review
- Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state.Molecular medicine (Cambridge, Mass.) · 2026Article
- A highly abundant circular RNA from the RMST locus plays a role in posterior fossa ependymoma pathogenesis.Brain pathology (Zurich, Switzerland) · 2026Article
- Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny.The Journal of clinical investigation · 2026Article
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Article
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.Nature genetics · 2026Article
- GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma.Cell reports · 2026Article
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
Corrections and comments
- Update of
Authors and funding
25 authors.
Rodrigo RomeroHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9388-8306
Tinyi Chu *Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3369-6692
Tania J González Robles *Institute of Systems Genetics, Department of Precision Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-9292-382X
Perianne Smith *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yubin XieProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2542-2544
Harmanpreet KaurHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sara YoderDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Huiyong ZhaoAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chenyi MaoMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria V PulinaMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kayla E LawrenceHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anuradha GopalanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samir ZaidiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kwangmin YooDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0002-8614-0973
Ning FanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Olivia GerstnerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wouter R KarthausHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa DeStanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kelly V RugglesInstitute of Systems Genetics, Department of Precision Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-0152-0863
Peter M K WestcottCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.ORCID 0000-0001-9436-4857
Ronan ChalignéProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4332-3291
Dana Pe'erProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9259-8817
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. sawyersc@mskcc.org.ORCID 0000-0003-4955-6475
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSingle-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MThe Center for Tumor-Immune Systems Biology at MSKCCU54CA274492 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christina S Leslie · 2022 to 2026
$16.3MProject 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4MTumor-specific T cell state dynamics and heterogeneity in early tumorigenesisU54CA209975 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LESLIE, CHRISTINA S, RUDENSKY, ALEXANDER Y · 2016 to 2021
$11.8MProject 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando · 2022 to 2026
$11.6MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MTraining Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MCharles H. Revson Foundation 22-23Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRQ: 10-21NCI NIH HHS K08 CA282978NCI NIH HHS K22 CA279501NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA045508NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA209975NCI NIH HHS U54 CA224079NCI NIH HHS U54 CA263001NCI NIH HHS U54 CA274492NIGMS NIH HHS T32 GM136542U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA008748U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA092629U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA155169U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA193837U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA224079U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA274492U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA282978U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA209975
Abstract
Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate neuroendocrine lineage transformation throughout prostate cancer progression. Transplanted mouse prostate organoids with human-relevant driver mutations (Rb1
Indexed as
Basic Helix-Loop-Helix ProteinsProstatic NeoplasmsAdenocarcinomaAnimalsCarcinoma, NeuroendocrineCell LineageHumansMaleMiceNeuroendocrine CellsNeuroendocrine TumorsOrganoidsRetinoblastoma Binding ProteinsTumor MicroenvironmentASCL1 protein, humanAscl1 protein, mouseBasic Helix-Loop-Helix ProteinsRetinoblastoma Binding Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.